LC-MS-MS检测血清载脂蛋白的酶解效率.pdfVIP

LC-MS/MS检测血清载脂 蛋白的酶解效率 上海市临床检验中心 李卿 IFCC于1991-1993年成立的载 脂蛋白标准化工作组，其值由 该工作组的组织方，即“美国 华盛顿大学西北脂类代谢和糖 尿病研究实验室”，使用免疫 法（作为参考方法）确定。 1996年IFCC在美国国家疾控中 心建立的载脂蛋白参考方法研 究工作组发表研究成果，即使 用同位素稀释质谱法定量 apoA- Ⅰ。 主要原因是免疫法可能会受交 差反应、抗体亲和力减弱、抗 原表位变性等因素影响。 Apolipoproteins by Mass Spectrometry (WG-APO MS) • Terms of Reference • To achieve standardization of a panel of clinically relevant serum apolipoproteins (apo) A-I, B, C-I, C-II , C-III, E and apo (a) (including qualitative phenotyping where needed). Standardization is done in such a way that measurement results are traceable to SI as outlined in ISO 17511. Other traceability chains will be used in cases where traceability to SI cannot be achieved. • To evaluate clinical performance and clinical utility of serum apolipoprotein panel(s) for CVD risk stratification and treatment, in comparison to or together with contemporary blood lipids. • Current projects • Define the analytes / measurands intended to be measured. • Development of primary and secondary reference materials, including evaluation of commutability. • Development of an LC-MS/MS-based reference method for the above mentioned analytes that are unaffected by genetic variants, post-translational modifications and other factors. The reference method will meet relevant ISO standards (i.e., ISO 15195). • Evaluation of the analytical performance of the LC-MS/MS reference method. • Assessment of the performance of commercially available apolipoprotein assays compared to the reference method using commutable reference materials as well as single donation samples. • Any reference materials and reference measurement procedures developed will be submitted to JCTLM for review and listing on the JCTLM database. • Future Projects • Evaluation of clinical performance and clinical utility of the multiplexed apolipoprotein test according to the